FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
58.887,00 -1.526,02 (-2,53%)
Gilead Sciences, Inc. (0QYQ.IL)
| Chiusura precedente | 65,98 |
| Aperto | 65,49 |
| Denaro | 62,41 x N/D |
| Lettera | 68,64 x N/D |
| Min-Max giorno | 64,74 - 65,89 |
| Intervallo di 52 settimane | 64,74 - 87,53 |
| Volume | |
| Media Volume | 50.291 |
| Capitalizzazione | 81,576B |
| Beta (5 anni mensile) | 0,35 |
| Rapporto PE (ttm) | 15,05 |
| EPS (ttm) | 4,35 |
| Prossima data utili | 25 apr 2024 |
| Rendimento e dividendo (futuro) | 3,00 (3,81%) |
| Data ex dividendo | 14 set 2023 |
| Stima target 1A | N/D |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireCenter for Disease Analysis Foundation Announces Receipt of an $8 Million Grant from Gilead Sciences to Relink Hepatitis B and C Patients to Care in the United States
LAFAYETTE, Colo., July 20, 2023 (GLOBE NEWSWIRE) -- The Center for Disease Analysis Foundation (CDA Foundation) announced today that it received an $8 million grant from Gilead Sciences (Nasdaq: GILD) as part of Gilead’s Relink grant program. CDA Foundation will disperse the grant to qualifying tax-exempt organizations to contact diagnosed but untreated patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection to bring them back into care. Despite the availability of existing tr
